Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia

Key Findings:

1. Immune Reconstitution: The patient showed rapid and stable engraftment by day +15 post-transplantation. The T-cell lymphopenia was corrected, and there was an increase in serum immunoglobulins, particularly IgA and IgG2, to normal levels.
2. Neurological Outcome: The patient exhibited milder progression of ataxic symptoms during the 6-year follow-up compared to age-matched A-T patients. His neurological impairment increased up to 14 points at 9 years of age, compared to a median of 19 points in eleven age-matched classical A-T patients.
3. Malignancy Prevention: The report emphasizes the need for novel preventive and curative treatment options for malignancies in A-T. AlloHSCT is presented as an encouraging approach to correct immunity and prevent the development of hematologic malignancies.
4. Reduced Intensity Conditioning (RIC): A RIC regimen was used for the transplantation, which included fludarabine, cyclophosphamide, and rabbit anti-thymocyte globulin. This was crucial as A-T patients are sensitive to the toxicity of conventional conditioning regimens.
5. Patient Characteristics: The patient had very low naïve T cells, an absence of IgA, and low IgG2 and IgG4. He also had a compound heterozygous mutation in the ATM gene.
6. Long-term Follow-up: On long-term follow-up, the patient gained height and weight, and his serum alpha-fetoprotein (AFP) levels increased slowly.

The report concludes that alloHSCT could be a viable pre-emptive treatment strategy for some A-T patients, although more research is needed to confirm these findings.